首页|Suzhou University of Science and Technology Researcher Has Provided New Study Fi ndings on Machine Learning (Machine Learning Empowering Drug Discovery: Applicat ions, Opportunities and Challenges)
Suzhou University of Science and Technology Researcher Has Provided New Study Fi ndings on Machine Learning (Machine Learning Empowering Drug Discovery: Applicat ions, Opportunities and Challenges)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-Researchers detail new data in artific ial intelligence. According to news reporting from Suzhou, People's Republic of China, by NewsRx journalists, research stated, "Drug discovery plays a critical role in advancing human health by developing new medications and treatments to c ombat diseases." Funders for this research include National Natural Science Foundation of China; Postgraduate Research & Practice Innovation Program of Jiangsu Pro vince. The news correspondents obtained a quote from the research from Suzhou Universit y of Science and Technology: "How to accelerate the pace and reduce the costs of new drug discovery has long been a key concern for the pharmaceutical industry. Fortunately, by leveraging advanced algorithms, computational power and biologi cal big data, artificial intelligence (AI) technology, especially machine learni ng (ML), holds the promise of making the hunt for new drugs more efficient." According to the news reporters, the research concluded: "Recently, the Transfor mer-based models that have achieved revolutionary breakthroughs in natural langu age processing have sparked a new era of their applications in drug discovery. H erein, we introduce the latest applications of ML in drug discovery, highlight t he potential of advanced Transformer-based ML models, and discuss the future pro spects and challenges in the field."
Suzhou University of Science and Technol ogySuzhouPeople's Republic of ChinaAsiaCyborgsDrugs and TherapiesEme rging TechnologiesMachine Learning
NETL
NSTL
